Thera-SAbDab

TISOTUMAB

>   Structural Summary
TherapeuticTisotumab
TargetF3
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSS
Light ChainDIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedGenmab, Seattle Genetics
Conditions Approvedna
Conditions ActiveBladder cancer, Cervical cancer, Endometrial cancer, Fallopian tube cancer, Oesophageal cancer, Ovarian cancer, Peritoneal cancer, Prostate cancer, Solid tumours
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]